TIDMNUT
RNS Number : 2937Q
Elder Pharmaceuticals Ltd
07 April 2009
?
Elder Pharmaceuticals Ltd
7 April 2009
For immediate release
Elder Pharmaceuticals Limited
Statement re: NeutraHealth plc
Further to its announcement on 26 March 2009, Elder Pharmaceuticals Limited
('Elder') confirms that it is still considering its options with regard to its
investment in NeutraHealth plc ('NeutraHealth'), which may or may not involve an
offer for NeutraHealth.
For the avoidance of doubt, if any offer for NeutraHealth is made, it will be
made by Elder International FZCO, a wholly owned subsidiary of Elder
Pharmaceuticals Limited. In addition, any offer, if made, will be solely in
cash.
Enquiries:
Jagdish Saxena (Managing Director)
Elder Pharmaceuticals Limited
00 91 22 2673 0058
David McCorquodale
KPMG Corporate Finance
020 7311 1000
KPMG Corporate Finance, a division of KPMG LLP which is authorised and regulated
by the Financial Services Authority for investment business activities, is
acting for Elder as financial adviser in relation to the matters set out in this
announcement and is not acting for any other person in relation to these
matters. KPMG Corporate Finance will not be responsible to anyone other than
Elder for providing the protections afforded to its clients or for providing
advice in relation to the contents of this announcement.
Dealing Disclosure Requirements:
Under the provisions of Rule 8.3 of the Takeover Code (the 'Code'), if any
person is, or becomes, 'interested' (directly or indirectly) in one per cent. or
more of any class of 'relevant securities' of NeutraHealth, all 'dealings' in
any 'relevant securities' of that company (including by means of an option in
respect of, or a derivative referenced to, any such 'relevant securities') must
be publicly disclosed by no later than 3.30 pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the 'offer period' otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
'interest' in 'relevant securities' of NeutraHealth, they will be deemed to be a
single person for the purpose of Rule 8.3.
Under the provisions of Rule 8.1 of the Code, all 'dealings' in 'relevant
securities' of NeutraHealth by Elder or NeutraHealth, or by any of their
respective 'associates', must be disclosed by no later than 12.00 noon (London
time) on the London business day following the date of the relevant transaction.
A disclosure table, giving details of the companies in whose 'relevant
securities' 'dealings' should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.
'Interests in securities' arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an 'interest' by
virtue of the ownership or control of securities, or by virtue of any option in
respect of, or derivative referenced to, securities.
Terms in quotation marks are defined in the Code. If you are in any doubt as to
whether or not you are required to disclose a 'dealing' under Rule 8, you should
consult the Takeover Panel.
This information is provided by RNS
The company news service from the London Stock Exchange
END
STRIRMJTMMAMBIL
|